Primary oral manifestation of Langerhans cell histiocytosis refractory to conventional therapy but susceptible to BRAF-specific treatment: a case report and review of the literature.

Abstract

Langerhans cell histiocytosis (LCH) is a diagnostic and therapeutic challenge. We report on a rare case of its primary oral manifestation that was treated successfully with the BRAF-specific agent, vemurafenib, after insufficient standard LCH treatment. This case underlines the importance of proper diagnosis and the evaluation of targeted therapy as a valuable tool in LCH treatment. Furthermore, the close collaboration of surgeons, oncologists, and dentists is mandatory to ensure adequate treatment, restore the stomatognathic system in debilitating post-treatment situations, improve quality of life, and ensure effective disease control in infants and young patients.

• Authors: Norbert Neckel, Andrej Lissat, Arendt von Stackelberg, Nadine Thieme, Mohemed-Salim Doueiri, Birgit Spors, Benedicta Beck-Broichsitter, Max Heiland, Jan-Dirk Raguse
• Journal: Therapeutic advances in medical oncology (Ther Adv Med Oncol) Vol. 11 Pg. 1758835919878013 ( 2019) ISSN: 1758-8340 [Print] England
• PMID: 31666812 (Publication Type: Case Reports)
• Copyright: © The Author(s), 2019.